These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 6987190

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The immunotherapy of prostate and bladder cancer.
    Totterman TH, Loskog A, Essand M.
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prostate cancer vaccines: current status.
    Hwang LC, Fein S, Levitsky H, Nelson WG.
    Semin Oncol; 1999 Apr; 26(2):192-201. PubMed ID: 10597730
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunology and immunotherapy approaches for prostate cancer.
    Elkord E.
    Prostate Cancer Prostatic Dis; 2007 Apr; 10(3):224-36. PubMed ID: 17420764
    [Abstract] [Full Text] [Related]

  • 9. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
    Prikler L, Scandella E, Men Y, Engeler DS, Diener PA, Gillessen S, Ludewig B, Schmid HP.
    Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Standard treatments induce antigen-specific immune responses in prostate cancer.
    Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, Blood P, Pai H, Ludgate C, Nelson BH.
    Clin Cancer Res; 2007 Mar 01; 13(5):1493-502. PubMed ID: 17332294
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
    Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J.
    Int J Oncol; 2008 Mar 01; 32(3):527-35. PubMed ID: 18292929
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, Czerniecki BJ, Shu S.
    Crit Rev Immunol; 2001 Mar 01; 21(1-3):215-48. PubMed ID: 11642606
    [Abstract] [Full Text] [Related]

  • 18. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG.
    Cancer Res; 1999 Oct 15; 59(20):5160-8. PubMed ID: 10537292
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE, Miller M, Davol PA, Grabert RC, Davis JB, Lum LG.
    Anticancer Res; 2005 Oct 15; 25(1A):43-52. PubMed ID: 15816517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.